surgumedВестник СурГУ. МедицинаVestnik SurGU. Meditsina2949-3447Сургутский государственный университет10.35266/2949-3447-2023-4-9surgumed-704Research ArticleМЕДИКО-БИОЛОГИЧЕСКИЕ НАУКИ. ОБЗОР ЛИТЕРАТУРЫLIFE SCIENCES. REVIEWSСОВРЕМЕННЫЙ ВЗГЛЯД НА ТРАДИЦИОННЫЕ МАРКЕРЫ ПРИ СЕПСИСЕA MODERN LOOK AT TRADITIONAL MARKERS IN SEPSIShttps://orcid.org/0000-0003-1145-3710НаумоваЛюдмила АлексеевнаNaumovaLyudmila A.

доктор медицинских наук, профессор

Doctor of Sciences (Medicine), Professor

naumovala@yandex.ruhttps://orcid.org/0009-0001-0518-1213ЯллыевМудринат БатырсолтановичYallyevMudrinat B.

аспирант, врач – анестезиолог-реаниматолог

Postgraduate, Anesthesiologist-Resuscitator

Сургутский государственный университет, СургутРоссияSurgut State University, SurgutRussian Federation2023211220231646169Copyright © Наумова Л.А., Яллыев М.Б., 20232023Наумова Л.А., Яллыев М.Б.Naumova L.A., Yallyev M.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surgumed.ru/jour/article/view/704

Цель – анализ современных представлений об известных маркерах сепсиса, новых знаний об их патофизиологической роли и значении в оценке тяжести, эффективности лечения и прогноза при сепсисе. Поиск литературы проводился с использованием следующих электронных информационных ресурсов: КиберЛенинка, PubMed, Nature Pathology, MEDLINE, PLOS ONE. Глубина поиска преимущественно не превышала 7–10 лет и определялась фундаментальностью работ. Используемые при поиске ключевые слова – маркеры воспаления и клеточного повреждения, лактатдегидрогеназа, С-реактивный белок, сепсис. Опубликованные в последние годы результаты многочисленных исследований широко доступных клинической практике биомаркеров различных заболеваний, включая сепсис, в частности лактатдегидрогеназы и С-реактивного белка, отражают расширение и углубление наших представлений о патофизиологической роли этих маркеров. Полученные данные могут иметь важное диагностическое, терапевтическое и прогностическое значение. Вместе с тем, пока нет однозначного понимания значения тех или иных маркеров как в ранней диагностике сепсиса, так и оценке тяжести его течения и прогноза, а также нет четко сформированного отношения к их значению. Это в некоторой степени объясняется отсутствием дифференцированного подхода к изучению, в частности различных изоформ С-реактивного белка, а также отсутствием доступности широкой практике современных высокочувствительных методов определения уровней маркеров, что порождает порой противоречивые выводы об их значении. Вместе с тем лактатдегидрогеназа и С-реактивный белок могут информировать о важнейших процессах в организме пациента, в том числе недоступных оценке другими методами и, следовательно, помочь в принятии клинических решений, в частности выборе адекватной и своевременной антибактериальной терапии. Данные литературы также свидетельствуют о необходимости продолжения исследований патофизиологической роли этих биомаркеров при сепсисе и других заболеваниях человека с использованием высокочувствительных методов их определения.

The study aims to examine modern views of common sepsis markers, new data on their pathophysiological role and significance in determining the severity, efficacy of care, and prognosis of sepsis. The literature was searched for in such information sources as CyberLeninka, PubMed, Nature Pathology, MEDLINE, and PLOS ONE. The search depth was primarily 7–10 years and included only fundamental publications. The keywords used in the study are markers of inflammation and cellular damage, lactate dehydrogenase, C-reactive protein, and sepsis. A comprehensive understanding of the pathophysiological significance of widely available in clinical practice biomarkers of many diseases, including sepsis, such as lactate dehydrogenase and C-reactive protein, is made possible by the results of numerous recently published research on these markers. The data obtained may provide diagnostic, therapeutic, and prognostic significance. At the same time, there is no unambiguous opinion on and understanding of certain markers both in the early diagnosis of sepsis and in the assessment of the severity of its course and prognosis. The absence of differentiated research approaches used for various isoforms of C-reactive protein and the accessibility of modern highly sensitive methods for determining the markers’ level to widespread use are the partial reasons for that, which results in controversial findings about their significance. Additionally, lactate dehydrogenase and C-reactive protein can portray important processes in a patient’s organism, including those unavailable for assessment via other methods. Therefore, they can help in decision-making in the clinical process, particularly in selecting an adequate and timely antibacterial therapy. The literature data also suggests that more research into the pathophysiologic role of these biomarkers in sepsis and other human diseases using highly sensitive methods is required.

маркеры воспаления и клеточного повреждениялактатдегидрогеназаС-реактивный белоксепсисmarkers of inflammation and cellular damagelactate dehydrogenaseC-reactive proteinsepsisReferencesPierrakos C., Velissaris D., Bisdorff M. et al. Biomarkers of sepsis: Time for a reappraisal. Crit Care. 2020;24(1):287.Pierrakos C., Velissaris D., Bisdorff M. et al. Biomarkers of sepsis: Time for a reappraisal. Crit Care. 2020;24(1):287.Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.Rhodes A., Evans L. E., Alhazzani W. et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45(3):486–552. DOI 10.1097/CCM.0000000000002255.Rhodes A., Evans L. E., Alhazzani W. et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45(3):486–552. DOI 10.1097/CCM.0000000000002255.Singer M., Deutschman C. S., Seymour C. W et al. The Third International Consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801–810.Singer M., Deutschman C. S., Seymour C. W et al. The Third International Consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801–810.Pierrakos C., Vincent J. L. Sepsis biomarkers: A review. Crit Care. 2010;14(1):R15.Pierrakos C., Vincent J. L. Sepsis biomarkers: A review. Crit Care. 2010;14(1):R15.Falcão-Holanda R. B., Brunialti M. K. C., Jasiulionis M. G. et al. Epigenetic regulation in sepsis, role in pathophysiology and therapeutic perspective. Front Med (Lausanne). 2021;8:685333.Falcão-Holanda R. B., Brunialti M. K. C., Jasiulionis M. G. et al. Epigenetic regulation in sepsis, role in pathophysiology and therapeutic perspective. Front Med (Lausanne). 2021;8:685333.Pletcher M. J., Pignone M. Evaluating the clinical utility of a biomarker: A review of methods for estimating health impact. Circulation. 2011;123(10):1116–1124.Pletcher M. J., Pignone M. Evaluating the clinical utility of a biomarker: A review of methods for estimating health impact. Circulation. 2011;123(10):1116–1124.Schultz M., Rasmussen L. J. H., Andersen M. H. et al. Use of the prognostic biomarker suPAR in the emergency department improves risk stratification but has no effect on mortality: A cluster-randomized clinical trial (TRIAGE III). Scand J Trauma Resusc Emerg Med. 2018;26(1):69.Schultz M., Rasmussen L. J. H., Andersen M. H. et al. Use of the prognostic biomarker suPAR in the emergency department improves risk stratification but has no effect on mortality: A cluster-randomized clinical trial (TRIAGE III). Scand J Trauma Resusc Emerg Med. 2018;26(1):69.Наумова Л. А., Яллыев М. Б. Особенности коморбидности и течения сепсиса у онкогематологических больных // Вестник СурГУ. Медицина. 2023. Т. 16, № 3. С. 83–88. DOI 10.35266/2304-9448-2023-3-83-88.Наумова Л. А., Яллыев М. Б. Особенности коморбидности и течения сепсиса у онкогематологических больных // Вестник СурГУ. Медицина. 2023. Т. 16, № 3. С. 83–88. DOI 10.35266/2304-9448-2023-3-83-88.Mishra D., Banerjee D. Lactate dehydrogenases as metabolic links between tumor and stroma in the tumor microenvironment. Cancers (Basel). 2019;11(6):750.Mishra D., Banerjee D. Lactate dehydrogenases as metabolic links between tumor and stroma in the tumor microenvironment. Cancers (Basel). 2019;11(6):750.Iepsen U. W., Plovsing R. R., Tjelle K. et al. The role of lactate in sepsis and COVID-19: Perspective from contracting skeletal muscle metabolism. Exp Physiol. 2022;107(7):665–673.Iepsen U. W., Plovsing R. R., Tjelle K. et al. The role of lactate in sepsis and COVID-19: Perspective from contracting skeletal muscle metabolism. Exp Physiol. 2022;107(7):665–673.Gattinoni L., Vasques F., Camporota L. et al. Understanding lactatemia in human sepsis. Potential impact for early management. Am J Respir Crit Care Med. 2019;200(5):582–589.Gattinoni L., Vasques F., Camporota L. et al. Understanding lactatemia in human sepsis. Potential impact for early management. Am J Respir Crit Care Med. 2019;200(5):582–589.Nielsen H. B., Febbraio M. A., Ott P. et al. Hepatic lactate uptake versus leg lactate output during exercise in humans. J Appl Physiol (1985). 2007;103(4):1227–1233.Nielsen H. B., Febbraio M. A., Ott P. et al. Hepatic lactate uptake versus leg lactate output during exercise in humans. J Appl Physiol (1985). 2007;103(4):1227–1233.Certo M., Tsai C. H., Pucino V. et al. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat Rev Immunol. 2021;21(3):151–161.Certo M., Tsai C. H., Pucino V. et al. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat Rev Immunol. 2021;21(3):151–161.Matthay M. A., Zemans R. L. The acute respiratory distress syndrome: Pathogenesis and treatment. Annu Rev Pathol. 2011;6:147–163.Matthay M. A., Zemans R. L. The acute respiratory distress syndrome: Pathogenesis and treatment. Annu Rev Pathol. 2011;6:147–163.Henry B. M., Aggarwal G., Wong J. et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am J Emerg Med. 2020;38(9):1722–1726.Henry B. M., Aggarwal G., Wong J. et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am J Emerg Med. 2020;38(9):1722–1726.Castro V. M., McCoy T. H., Perlis R. H. laboratory findings associated with severe illness and mortality among hospitalized individuals with coronavirus disease 2019 in Eastern Massachusetts. JAMA Netw Open. 2020;3(10):e2023934.Castro V. M., McCoy T. H., Perlis R. H. laboratory findings associated with severe illness and mortality among hospitalized individuals with coronavirus disease 2019 in Eastern Massachusetts. JAMA Netw Open. 2020;3(10):e2023934.Brooks G. A. The science and translation of lactate shuttle theory. Cell Metab. 2018;27(4):757–785.Brooks G. A. The science and translation of lactate shuttle theory. Cell Metab. 2018;27(4):757–785.Puthucheary Z. A., Astin R., Mcphail M. J. W. et al. Metabolic phenotype of skeletal muscle in early critical illness. Thorax. 2018;73:926–935.Puthucheary Z. A., Astin R., Mcphail M. J. W. et al. Metabolic phenotype of skeletal muscle in early critical illness. Thorax. 2018;73:926–935.Algebaly H. F., Abd-Elal A., Kaffas R. E. et al. Predictive value of serum lactate dehydrogenase in diagnosis of septic shock in critical pediatric patients: A cross-sectional study. J Acute Dis. 2021;10(3):107–111.Algebaly H. F., Abd-Elal A., Kaffas R. E. et al. Predictive value of serum lactate dehydrogenase in diagnosis of septic shock in critical pediatric patients: A cross-sectional study. J Acute Dis. 2021;10(3):107–111.Frenkel A., Shiloh A., Azulay B. et al. The role of lactate dehydrogenase in hospitalized patients, comparing those with pulmonary versus non-pulmonary infections: A nationwide study. PLOS ONE. 2023;18(3):e0283380.Frenkel A., Shiloh A., Azulay B. et al. The role of lactate dehydrogenase in hospitalized patients, comparing those with pulmonary versus non-pulmonary infections: A nationwide study. PLOS ONE. 2023;18(3):e0283380.Muchtar E., Dispenzieri A., Lacy M. Q. et al. Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. Br J Haematol. 2017;178(6):888–895.Muchtar E., Dispenzieri A., Lacy M. Q. et al. Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. Br J Haematol. 2017;178(6):888–895.Sproston N. R., Ashworth J. J. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754.Sproston N. R., Ashworth J. J. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754.Karlsson J., Wetterö J., Weiner M. et al. Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity. Arthritis Res Ther. 2022;24(1):139.Karlsson J., Wetterö J., Weiner M. et al. Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity. Arthritis Res Ther. 2022;24(1):139.Plebani M. Why C-reactive protein is one of the most requested tests in clinical laboratories? Clin Chem Lab Med. 2023;61(9):1540–1545.Plebani M. Why C-reactive protein is one of the most requested tests in clinical laboratories? Clin Chem Lab Med. 2023;61(9):1540–1545.An Q. Q., Feng X. Z., Zhan T. et al. A simple synthesis of a core-shell structure PPy-Au nanocomposite for immunosensing of C-reactive protein. Talanta. 2024;267:125158.An Q. Q., Feng X. Z., Zhan T. et al. A simple synthesis of a core-shell structure PPy-Au nanocomposite for immunosensing of C-reactive protein. Talanta. 2024;267:125158.Puspitasari Y. M., Ministrini S., Schwarz L. et al. modern concepts in cardiovascular disease: Inflamm-aging. Front Cell Dev Biol. 2022;10:882211.Puspitasari Y. M., Ministrini S., Schwarz L. et al. modern concepts in cardiovascular disease: Inflamm-aging. Front Cell Dev Biol. 2022;10:882211.Luzzani A., Polati E., Dorizzi R. et al. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med. 2003;31(6):1737–1741.Luzzani A., Polati E., Dorizzi R. et al. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med. 2003;31(6):1737–1741.Simon L., Saint-Louis P., Amre D. K. et al. Procalcitonin and C-reactive protein as markers of bacterial infection in critically ill children at onset of systemic inflammatory response syndrome. Pediatr Crit Care Med. 2008;9(4):407–413.Simon L., Saint-Louis P., Amre D. K. et al. Procalcitonin and C-reactive protein as markers of bacterial infection in critically ill children at onset of systemic inflammatory response syndrome. Pediatr Crit Care Med. 2008;9(4):407–413.Park J. H., Kim D. H., Jang H. R. et al. Clinical relevance of procalcitonin and C-reactive protein as infection markers in renal impairment: A cross-sectional study. Crit Care. 2014;18(6):640.Park J. H., Kim D. H., Jang H. R. et al. Clinical relevance of procalcitonin and C-reactive protein as infection markers in renal impairment: A cross-sectional study. Crit Care. 2014;18(6):640.Hattori T., Nishiyama H., Kato H. et al. Clinical value of procalcitonin for patients with suspected bloodstream infection. Am J Clin Pathol. 2014;141(1):43–51.Hattori T., Nishiyama H., Kato H. et al. Clinical value of procalcitonin for patients with suspected bloodstream infection. Am J Clin Pathol. 2014;141(1):43–51.Han J. H., Nachamkin I., Coffin S. E. et al. Use of a combination biomarker algorithm to identify medical intensive care unit patients with suspected sepsis at very low likelihood of bacterial infection. Antimicrob Agents Chemother. 2015;59(10):6494–6500.Han J. H., Nachamkin I., Coffin S. E. et al. Use of a combination biomarker algorithm to identify medical intensive care unit patients with suspected sepsis at very low likelihood of bacterial infection. Antimicrob Agents Chemother. 2015;59(10):6494–6500.Póvoa P., Teixeira-Pinto A. M., Carneiro A. H. et al. C-reactive protein, an early marker of community-acquired sepsis resolution: A multi-center prospective observational study. Crit Care. 2011;15(4):R169.Póvoa P., Teixeira-Pinto A. M., Carneiro A. H. et al. C-reactive protein, an early marker of community-acquired sepsis resolution: A multi-center prospective observational study. Crit Care. 2011;15(4):R169.Van der Does Y., Limper M., Jie K. E. et al. Procalcitonin-guided antibiotic therapy in patients with fever in a general emergency department population: A multicentre non-inferiority randomized clinical trial (HiTEMP study). Clin Microbiol Infect. 2018;24(12):1282–1289.Van der Does Y., Limper M., Jie K. E. et al. Procalcitonin-guided antibiotic therapy in patients with fever in a general emergency department population: A multicentre non-inferiority randomized clinical trial (HiTEMP study). Clin Microbiol Infect. 2018;24(12):1282–1289.Wirz Y., Meier M. A., Bouadma L. et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: A patient-level meta-analysis of randomized trials. Crit Care. 2018;22(1):191.Wirz Y., Meier M. A., Bouadma L. et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: A patient-level meta-analysis of randomized trials. Crit Care. 2018;22(1):191.Huang D. T., Yealy D. M., Filbin M. R. et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018;379(3):236–249.Huang D. T., Yealy D. M., Filbin M. R. et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018;379(3):236–249.Jämsä J., Ala-Kokko T., Huotari V. et al. Neutrophil CD64, C-reactive protein, and procalcitonin in the identification of sepsis in the ICU – Post-test probabilities. J Crit Care. 2018;43:139–142.Jämsä J., Ala-Kokko T., Huotari V. et al. Neutrophil CD64, C-reactive protein, and procalcitonin in the identification of sepsis in the ICU – Post-test probabilities. J Crit Care. 2018;43:139–142.Muzlovic I., Ihan A., Stubljar D. CD64 index on neutrophils can diagnose sepsis and predict 30-day survival in subjects after ventilator-associated pneumonia. J Infect Dev Ctries. 2016;10(3):260–268.Muzlovic I., Ihan A., Stubljar D. CD64 index on neutrophils can diagnose sepsis and predict 30-day survival in subjects after ventilator-associated pneumonia. J Infect Dev Ctries. 2016;10(3):260–268.Zong H., Shang X., Wang X. et al. Diagnosis of septic shock by serum measurement of human neutrophil lipocalin by a rapid homogeneous assay. J Immunol Methods. 2023;522:113570.Zong H., Shang X., Wang X. et al. Diagnosis of septic shock by serum measurement of human neutrophil lipocalin by a rapid homogeneous assay. J Immunol Methods. 2023;522:113570.Ding Z., Wei Y., Peng J. et al. The potential role of C-reactive protein in metabolic-dysfunction-associated fatty liver disease and aging. Biomedicines. 2023;11(10):2711.Ding Z., Wei Y., Peng J. et al. The potential role of C-reactive protein in metabolic-dysfunction-associated fatty liver disease and aging. Biomedicines. 2023;11(10):2711.Lu T. C., Yang Y. J., Zhong Y. et al. Simultaneous detection of C-reactive protein and lipopolysaccharide based on a dual-channel electrochemical biosensor for rapid Gram-typing of bacterial sepsis. Biosens Bioelectron. 2024;243:115772.Lu T. C., Yang Y. J., Zhong Y. et al. Simultaneous detection of C-reactive protein and lipopolysaccharide based on a dual-channel electrochemical biosensor for rapid Gram-typing of bacterial sepsis. Biosens Bioelectron. 2024;243:115772.

The authors declare that there are no conflicts of interest present.